Abstract Library

#4152 Valvular surgery in carcinoid heart disease – Indications and outcome

Introduction: Neuroendocrine tumors (NET) can release biogenic amines that can induce a fibrotic process in the heart valves known as carcinoid heart disease (CHD). Valvular replacement surgery is the standard of care, but such interventions are associated with significant morbidity and valid criteria for both selecting patients (pts) and timing of surgery are limited.

Conference:

Presenting Author:

Authors: Sponheim J, Beitnes J, Dahle G, Åvitsland T, Thiis-Evensen E,

Keywords: carcinoid heart disease, valvular surgery, prognostic factors,

#4147 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Cell-free DNA (cfDNA) 5-hydroxymethylcystosine (5hmC) analysis, a novel epigenomic technology, can detect changes in tumor gene expression and regulation in liquid biopsies.

Conference:

Presenting Author:

Authors: Sponheim J, Wong C, Thiis-Evensen E, Coruh C, Ning Y,

Keywords: [177Lu]Lu-DOTA-TATE, Lutathera, Peptide Receptor Radionuclide Therapy, Radioligand Therapy, Pancreatic Neuroendocrine Tumor, Biobank, 5-Hydroxymethylation,

#4136 Peptide receptor radionuclide treatment in an outpatient setting – A single center experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is an important treatment option for somatostatin receptor expressing non-resectable neuroendocrine tumors. Traditionally, this therapy has been provided as inpatient care. PRRT has been offered by Oslo University Hospital from November 2019, and organized mainly as outpatient care.

Conference:

Presenting Author:

Authors: Sponheim J, Dahle V, Skrede Mordal K, Solberg H, Åvitsland T,

Keywords: PRRT, outpatient care,

#3474 The prevalence of neuroendocrine neoplasms in Norway

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumors originating from neuroendocrine cells comprising of neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC).

Conference:

Presenting Author:

Authors: Thiis-Evensen E, Åvitsland T, Sponheim J,

Keywords: Prevalence, incidence, neuroendocrine neoplasm, neuroendocrine tumor, neuroendocrine carcinoma, epidemiology,

#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease

Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Thiis-Evensen E

Authors: Thiis-Evensen E, Sponheim J,

Keywords: Neuroendocrine tumor, Treatment, Radiology, Time to progression,